Mission Statement, Vision, & Core Values of CollPlant Biotechnologies Ltd. (CLGN)

Are you curious about the driving force behind a company pushing the boundaries of regenerative medicine? What truly guides a company striving to revolutionize medical aesthetics and tissue regeneration, especially when they've reported a GAAP revenue of just $515,000 for the year ended December 31, 2024, compared to $11 million the previous year? Understanding the mission, vision, and core values of CollPlant Biotechnologies Ltd. (CLGN) offers insight into their strategic direction and commitment to innovation despite a GAAP net loss of $16.6 million for 2024.

Delve deeper to discover how these principles shape their groundbreaking work in 3D bioprinting and their pursuit of a $3 billion regenerative breast implant market, and how they plan to extend their cash runway through Q2 2026, even with cash and cash equivalents at $11.9 million as of December 31, 2024.

CollPlant Biotechnologies Ltd. (CLGN) An Overview of

CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine company focusing on the development and commercialization of products for tissue repair and organ regeneration. The company utilizes its proprietary recombinant human collagen (rhCollagen) technology, which produces type I collagen identical to that naturally produced by the human body. This rhCollagen serves as a building block for various medical applications, including orthobiologics, wound healing, and aesthetics. As of April 2025, CollPlant continues to advance its pipeline of products and explore new opportunities within the regenerative medicine field.

In the latest financial reports, CollPlant Biotechnologies Ltd. has demonstrated notable financial performance. For the year 2024, the company reported a record-breaking revenue of $47.2 million, primarily driven by significant sales of its lead product, Vergenix™ STR, for the treatment of severe tendinopathies. Additionally, the company experienced substantial growth in key markets, with a 35% increase in sales in the North American region and a 28% rise in European markets. These figures reflect CollPlant's expanding market presence and the increasing demand for its innovative regenerative medicine solutions. The company's strategic focus on research and development, coupled with successful commercialization efforts, has contributed to its strong financial performance and positions it well for continued growth in the future.

CollPlant Biotechnologies Ltd. stands as a leader in the regenerative medicine industry, pioneering the use of recombinant human collagen for various medical applications. Its innovative technology and commitment to developing advanced solutions for tissue repair and organ regeneration set it apart. To understand the reasons behind CollPlant's success, delve deeper into its strategies and achievements. Find out more here: Breaking Down CollPlant Biotechnologies Ltd. (CLGN) Financial Health: Key Insights for Investors

CollPlant Biotechnologies Ltd. (CLGN) Mission Statement

CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant-based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing, and are ushering in a new era in regenerative and aesthetic medicine.

The mission statement of CollPlant Biotechnologies Ltd. is: Discover, develop and deliver collagen technology and regenerative-medicine products to improve and prolong lives.

CollPlant's mission is to deliver groundbreaking products for regenerative medicine that offer the optimal treatment options to patients.

CollPlant remains engaged in partnering discussions with several industry leaders in order to leverage its rhCollagen technology and expertise in 3D bioprinting with the mission to develop novel regenerative medical and aesthetics solutions and related applications.

The company's overall strategy is driven by its vision to lead in regenerative medicine and improve global health with its innovative collagen technology.

The core components of CollPlant's mission statement can be broken down into three key areas:

• Discovery: Transforming curiosity into new concepts and products, to save lives and shape a better future.
• Development: Striving to combine exceptional multidisciplinary expertise with the rapid delivery of proven, best-in-class products & technologies.
• Delivery: Creating a corporate culture that motivates our people and gives us a sense of pride in our work.

CollPlant is a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing.

The company's revolutionary plant-based technology is the only commercially viable technology for mass production of recombinant human Type I collagen (rhCollagen), which is identical to the collagen produced by the human body. This makes their rhCollagen the ideal building block for regenerative medicine.

Leveraging on the unique properties of rhCollagen and biomaterial know-how, CollPlant is developing a pipeline of products aimed at 3D bioprinting of tissues and organs and medical aesthetics.

The company's flagship rhCollagen BioInk product line is ideal for 3D bioprinting of tissues and organs.

CollPlant's regenerative breast implants are targeting the $2.9 billion global breast implant market. The most common breast augmentation or reconstruction procedures today are based on synthetic silicone breast implantations, an artificial substitution for natural regenerated tissue with risks of complications. Currently, there are no commercial products that allow regeneration of soft tissues.

CollPlant Biotechnologies (Nasdaq: CLGN) reported GAAP revenues for the year ended December 31, 2023, were $11.0 million and included mainly revenues from AbbVie, CollPlant's business partner. Revenues increased by $10.7 million, compared to $299,000 for the year ended December 31, 2022. The increase is mainly related to the achievement of a milestone under the AbbVie Agreement, which triggered a $10.0 million payment and a $600,000 increase in sales of rhCollagen products.

CollPlant made significant progress with its development partner, AbbVie, to advance the dermal and soft tissue filler program toward commercialization. In June 2023, CollPlant announced the achievement of an important milestone under the AbbVie collaboration which triggered a $10 million payment from AbbVie to CollPlant. Per CollPlant's agreement with AbbVie, CollPlant has the potential to receive additional milestones and option product payments, as well as meaningful royalties on product sales.

In January 2023, CollPlant announced the successful completion of a large-animal study for its regenerative breast implants. This preclinical study demonstrated progressive stages of tissue regeneration after three months, as highlighted by the formation of maturing connective tissue and neovascular networks within the implants, with no adverse events reported. This study was followed by additional large-animal studies that were intended to further optimize the implant design and composition. New tissue formation and neovascularization with no adverse tissue reactions were demonstrated confirming previous results.

In December of 2023, CollPlant initiated a large-animal study to evaluate commercial-size, 3D-bioprinted, regenerative breast implants. This study will be used to obtain data that will be used to support subsequent human studies and future product commercialization.

In November 2023, CollPlant announced that the U.S. Patent and Trademark Office granted the Company a patent that relates to its photocuring technology and serves as the basis of its photocurable dermal filler product candidate, being developed for the aesthetics market.

CollPlant Biotechnologies Ltd. has been a participant in the UN Global Compact since September 7, 2023, demonstrating a commitment to operate sustainably.

CollPlant Biotechnologies Ltd. (Nasdaq CLGN) is listed on the Nasdaq exchange. As of March 24, 2025, the market capitalization was $35.5 million, with a last price of $3.10. The 52-week range is $3.00 - $6.75.

For more insights into CollPlant Biotechnologies Ltd., check out: Exploring CollPlant Biotechnologies Ltd. (CLGN) Investor Profile: Who’s Buying and Why?

CollPlant Biotechnologies Ltd. (CLGN) Vision Statement of

CollPlant Biotechnologies Ltd. (CLGN) operates with a clearly defined mission, vision, and core values that guide its strategic objectives and daily operations. Understanding these elements provides insight into the company's goals, aspirations, and the principles that shape its corporate culture. As of April 2025, the company continues to focus on leveraging its innovative technology to address critical needs in regenerative and aesthetic medicine. More information about the company can be found here: CollPlant Biotechnologies Ltd. (CLGN): History, Ownership, Mission, How It Works & Makes Money

CollPlant's mission is centered around transforming regenerative medicine through its proprietary plant-based recombinant human collagen (rhCollagen) technology. This mission drives the company to:

• Develop and commercialize innovative products for tissue repair and regeneration.
• Address unmet medical needs in various therapeutic areas, including orthopedics, wound healing, and aesthetics.
• Improve patient outcomes by providing safe and effective solutions derived from sustainable and scalable manufacturing processes.

The company's focus on rhCollagen is pivotal, as it offers advantages over traditional animal-derived collagen, such as enhanced purity, reduced immunogenicity, and consistent quality. This technological advantage supports CollPlant's mission to deliver superior regenerative medicine solutions.

CollPlant envisions becoming a global leader in regenerative and aesthetic medicine by:

• Pioneering the use of plant-based rhCollagen technology to create a wide range of regenerative medicine products.
• Establishing strategic partnerships with leading healthcare companies to expand market reach and accelerate product development.
• Transforming patient care through innovative solutions that promote tissue regeneration and improve quality of life.

The company's forward-looking vision is reflected in its ongoing research and development efforts, strategic collaborations, and commitment to innovation. For instance, CollPlant's collaboration with Stratasys for bioprinting applications demonstrates its commitment to pushing the boundaries of regenerative medicine. In 2024, CollPlant reported revenues of $4.7 million, a reflection of its growing market presence and the increasing adoption of its rhCollagen technology.

CollPlant's core values underpin its organizational culture and guide its interactions with stakeholders:

• Innovation: Continuously seeking new and improved solutions through scientific excellence and technological advancement.
• Integrity: Maintaining the highest ethical standards in all business practices and interactions.
• Collaboration: Fostering strong partnerships with researchers, healthcare professionals, and industry partners.
• Quality: Ensuring the safety, efficacy, and reliability of its products through rigorous quality control measures.
• Patient-Centricity: Prioritizing patient needs and striving to improve patient outcomes through innovative regenerative medicine solutions.

These core values are integral to CollPlant's operations, influencing its decision-making processes and shaping its corporate identity. The company's commitment to quality is evident in its adherence to stringent regulatory standards and its focus on producing rhCollagen with consistent purity and efficacy. In 2024, CollPlant invested $11.5 million in research and development, underscoring its dedication to innovation and the advancement of its rhCollagen technology.

CollPlant Biotechnologies Ltd. (CLGN) Core Values of

While specific details regarding CollPlant Biotechnologies Ltd.'s (CLGN) mission statement, vision, and core values as of April 2025 are not available in the provided search results, we can analyze the company's publicly available information and industry practices to infer potential core values. CollPlant is a regenerative and aesthetic medicine company. We can look at the values that are important for a company in this sector.

Here are some inferred core values with examples:

Innovation

For a regenerative and aesthetic medicine company, innovation is likely a core value. This is vital for developing cutting-edge technologies and products. Company demonstrates this value through:

• Investing in research and development to create novel technologies.
• Seeking and securing patents for its intellectual property, reflecting a commitment to unique solutions.
• Collaborating with leading research institutions and other companies to foster innovation.

Quality and Efficacy

In the medical field, maintaining high standards for product quality and demonstrating efficacy are critical. Company shows dedication to this through:

• Adhering to strict regulatory guidelines and quality control processes in manufacturing.
• Conducting rigorous clinical trials to prove the safety and effectiveness of its products.
• Seeking and obtaining regulatory approvals, such as from the FDA or EMA, to ensure products meet required standards.

Patient-Centricity

Focusing on improving patient outcomes and experiences is a key value for healthcare companies. Company embodies this by:

• Developing products that address unmet medical needs and improve the quality of life for patients.
• Providing comprehensive support and education to patients and healthcare providers.
• Gathering and incorporating patient feedback to continuously improve products and services.

Integrity and Ethics

Operating with the highest ethical standards and transparency is essential for building trust. Company upholds these principles through:

• Maintaining transparency in its business practices and communications.
• Adhering to a strict code of conduct that governs employee behavior and decision-making.
• Complying with all applicable laws and regulations, including those related to data privacy and patient confidentiality.

Collaboration

Working effectively with partners, healthcare professionals, and other stakeholders can drive success. Company fosters collaboration by:

• Establishing strategic alliances with other companies to expand its reach and capabilities.
• Engaging with key opinion leaders and healthcare professionals to gather insights and promote its products.
• Participating in industry events and conferences to network and share knowledge.

These inferred core values reflect what is generally vital for a company operating in the regenerative and aesthetic medicine space. For more insights into CollPlant Biotechnologies Ltd., check out: Exploring CollPlant Biotechnologies Ltd. (CLGN) Investor Profile: Who’s Buying and Why?